Investors Invited to Lead the Treace Medical Securities Fraud Class Action Lawsuit
Treace Medical Class Action Lawsuit: A Call to Investors
Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating potential claims against Treace Medical Concepts, Inc. (NASDAQ: TMCI). Investors who incurred losses exceeding $50,000 between May 8, 2023, and May 7, 2024, are encouraged to discuss their legal options by contacting partner Josh Wilson at the firm. The urgency of the situation is heightened by the upcoming deadline of June 10, 2025, to file as a lead plaintiff in this federal securities class action lawsuit.
This investigation follows troubling revelations about Treace's financial performance and corporate governance. On May 7, 2024, the company announced a significant cut in its revenue guidance for the year, revising expectations down from between $220 million and $225 million to a new estimate of between $201 million and $211 million. This sharp decline in projected revenues stems from intensified competition in the market, particularly affecting their flagship product, the Lapiplasty 3D Bunion Correction System. In an earnings call held the same day, executives of Treace acknowledged that rival products, particularly minimally invasive osteotomy procedures and various
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.